Vistagen Inc has revealed new data from a preclinical study of its itruvone nasal spray, a potential treatment for major depressive disorder. The study showed that a single intranasal administration of itruvone was undetectable in the brain and most other tissues, supporting the proposed mechanism of action of the spray. Vistagen recently reported that itruvone is now staged for potential Phase 2B clinical development in the U.S. VTGN shares are up 1.69% at $1.80 on the last check Monday.